Preview

Рецепт

Расширенный поиск

Гиполипидемическая фармакотерапия с позиции последних рекомендаций

https://doi.org/10.34883/PI.2020.23.1.010

Полный текст:

Аннотация

Сердечно-сосудистые заболевания (ССЗ) уносят каждый год более 4 млн жизней. В развитии ССЗ, связанных с атеросклерозом, доказана роль таких факторов, как сахарный диабет (СД), дислипидемия, ожирение. В связи с этим очень важны профилактика и лечение ССЗ и выявление групп риска, угрожаемых по развитию атеросклероза. Доказана роль уровня холестерина (ХС) липопротеидов низкой плотности (ЛПНП), который является ключевым фактором в развитии атеросклероза. В то же время необходимо провести оценку показаний у пациентов различных групп риска по шкале SCORE для решения вопроса о необходимости назначения гиполипидемической терапии. Статины являются лекарственными средствами выбора для лечения дислипидемий с мощной доказательной базой. В настоящее время появились новые гиполипидемические средства, которые обладают минимальным количеством неблагоприятных лекарственных реакций и могут использоваться в комплексной терапии дислипидемий.

В статье проанализированы современные литературные данные и рекомендации Европейского общества кардиологов (ЕОК) по вопросам профилактики и лечения дислипидемий.

Об авторах

О. А. Гальцова
Белорусская медицинская академия последипломного образования
Беларусь

 Минск 



А. Г. Захаренко
Белорусская медицинская академия последипломного образования
Беларусь

 Минск 



Список литературы

1. Ference B.A., Ginsberg H.N, Graham I. (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, pp. 2459–72.

2. Holmes M.V., Asselbergs F.W., Palmer T.M. (2015) Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J, 36, pp. 539–50.

3. (2019) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifcation to reduce cardiovascular risk Authors/Task Force Members: Franc¸ois Mach. European Heart Journal, 178.

4. Catapano A.L., Graham I., De Backer G. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J, 37, pp. 2999–3058.

5. Jacobson T.A., Ito M.K., Maki K.C. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 – Full Report. J Clinical Lipidology.

6. Yezhov M., Sergienko I., Aronov D. (2017) Diagnosis and correction of lipid metabolism disorders with the purpose of prevention and treatment of atherosclerosis Russian recommendations VI revision. Atherosclerosis and dyslipidemia, 3 (28), pp. 5–22.

7. Devarai M.A. (2006) Direct demonstration of an anti-inflammatory effect of simvastatin. J. Clin. Endocrinol. Metab., 91, pp. 4489–4496.

8. Jantzen F. (2007) Isoprenoid depletion by statins antagonizes cytokine-induced downregulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial. J. Physiol. Pharmacol., 58 (3), pp. 503–14.

9. Kwak B. (2000) Statins as a newly recognized type of immunosuppressor. Nature Med., 6, pp. 1399–1402.

10. Gerasimov A., Isakov S., Chikin V. (2016) Endothelioprotection as a pleiotropic effect of various groups of pharmacological preparations. Science of the young, pp. 131–138 (in Russian).

11. Kalinin R., Suchkov I., Pshennikov A., Slepnev A. (2013) Effectiveness of L-arginine in the treatment of atherosclerosis of the arteries of the lower limbs and prevention of restenosis of the reconstruction area. Journal of the Ivanovsky Medical Academy, vol. 18, no 2, pp. 18–21.

12. Van der Harst P. (2008) Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron. Artery Dis., vol. 19, no 1, pp. 47–53.

13. Silverman M.G., Ference B.A., Im K. (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 316, pp. 1289–97.

14. Schwartz G.G., Olsson A.G., Ezekowitz M.D. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 285, pp. 1711–8.

15. Koskinas К.C., Siontis G.C.M., Piccolo R. (2018) Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J, 39, pp. 1172–80.

16. Wiviott S.D., Cannon C.P., Morrow D.A. (2005) Can low-density lipoprotein be too low? The safety and efcacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol, 46, pp. 1411–6.

17. Ridker P.M., Danielson E., Fonseca F.A. (2008) JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., vol. 359, no 21, pp. 2195–2207.

18. Yusuf S., Bosch J., Dagenais G. (2016) HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med.

19. Karpov Y., Talitsky K. (2016) Intensive hypolipidemic therapy: focus on rosuvastatin. Atmosphere news cardiology R, pp. 26–32 (in Russian).

20. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M. (2016) 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDLCholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol.

21. Jones P.H., Hunninghake D.B., Ferdinand K.C. (2004) Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther., vol. 26, no 9, pp. 1388–1399.

22. Crouse J.R., Raichlen J.S., Riley W.A. (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in l risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA, vol. 297, no 12, pp. 1344–1353.

23. Nissen S.E., Nicholls S.J., Sipahi I. (2006) ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, vol. 295, no 13, pp. 1556–1565.

24. Nissen S.E., Tuzcu E.M., Schoenhagen P. (2004) REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, vol. 291, no 9, pp. 1071–1080.

25. Sabatine M.S., Giugliano R.P., Keech A.C. (2017) FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 376, pp. 1713–22.

26. Han B., Eacho P.I., Knierman M.D. (2014) Isolation and characterization of the circulating truncated fоrm of PCSK9A. J. Lipid Res., vol. 55, no 7, pp. 1505–1514.

27. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol., vol. 32, no 7, pp. 1585–1595.

28. Cicero A.F., Tartagni E., Ertek S. 2014 Efcacy and safety profle of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin 9: the available clinical evidence. Expert Opin. Biol. Ther., vol. 14, no 6, pp. 863–868.

29. Dadu R.T., Ballantyne C.M. (2014) Lipid lowering with PCSK9 inhibitors. Nat. Rev. Cardiol., vol. 11, no 10, pp. 563–575.

30. Shapiro M.D., Fazio S., Tavori H. (2015) Targeting PCSK9 for therapeutic gains. Curr. Atheroscler. Rep., vol. 17, no 4, p. 499.

31. Raal F.J., Honarpour N., Blom D.J. (2015) TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomized, double-blind, placebo-controlled trial. Lancet, vol. 385, no 9965, pp. 341–350.

32. Chernyshov V., Rudyk Y. (2018) Correction of hypercholesterolemia in clinical practice: PCSK9 inhibitors - a new direction in hypolipidemic therapy. Rational pharmacotherapy, 4 (49), pp. 5–14.

33. Chaparro-Riggers J., Liang H., DeVay R.M. (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J. Biol. Chem., vol. 287, no 14, pp. 11090–11097.

34. Igawa T., Ishii S., Tachibana T. (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol., vol. 28, no 11, pp. 1203–1207.

35. Huijgen R., Fouchier S.W., Denoun M. (2012) Plasma levels of PSCK9 and phenotypic variability in familial hypercholesterolemia. J. Lipid Res., vol. 53, no 5, pp. 979–983.

36. Walton T.A., Nishtar S., Lumb P.J. (2015) Pro-protein convertase subtilisin/ kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. Int. J. Clin. Pract., vol. 69, no 7, pp. 738–742.

37. Cheng J.M., Oemrawsingh R., Garcia-Gracia H. (2014) Serum proprotein convertase subtilisin/kexin type 9 level is associated with coronary plaque inflammation and cardiovascular outcome independent from serum LDL level. Paper presented at American Heart Association Scientifc Sessions; November 7–11, 2014.

38. Guinzioni I., Tavori H., Covarrubias R., Major A., Linton M.F., Fazio S. Macrophage expression of PCSK9 influences atherosclerosis development. AHA Sci. Session, 2013. vol. 128, suppl. 2.

39. Raal F.J., Stein E.A., Dufour R. (2015) PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomized, double-blind, placebo-controlled trial. Lancet, vol. 385, pp. 331–340.

40. Shapiro M.D., Fazio S., Tavori H. (2015) Targeting PCSK9 for therapeutic gains. Curr. Atheroscler. Rep., vol. 17, no 4, p. 499.

41. Lambert G., Petrides F., Chatelais M. (2014) Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein recеptor defects. J. Am. Coll. Cardiol., vol. 63, no 33, pp. 2365–2373.


Рецензия

Для цитирования:


Гальцова О.А., Захаренко А.Г. Гиполипидемическая фармакотерапия с позиции последних рекомендаций. Рецепт. 2020;24(1):97-107. https://doi.org/10.34883/PI.2020.23.1.010

For citation:


Galtsova O., Zakharenko A. Hypolipidemic Pharmacotherapy from the Latest Recommendations. Recipe. 2020;24(1):97-107. (In Russ.) https://doi.org/10.34883/PI.2020.23.1.010

Просмотров: 20


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)